Heart check: experimental drug ziresovir put to the test in healthy adults
NCT ID NCT06591845
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This completed Phase 1 trial tested whether the experimental drug ziresovir affects the heart's electrical activity in 34 healthy adults. Participants received different doses of ziresovir, a placebo, and an active control (moxifloxacin) to compare effects. The main goal was to measure changes in the QT interval, a key heart rhythm safety marker. Results will help determine if ziresovir is safe for future studies in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
California Clinical Trials Medical Group, Inc.
Glendale, California, 91206, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ziresovir
What this could lead to
If successful, this study could confirm that ziresovir is safe for the heart, supporting its use in treating respiratory infections.
What could go wrong
This is an early-phase safety study in healthy people, not patients. It only looks at heart effects and does not test if the drug works for any disease.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.